Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* NYHA class II-III heart failure~* Ejection fraction equal to or below 35%~* On stable heart failure drug treatment~Exclusion Criteria:~* Considered medically inappropriate for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 10 mg ITI-214 (Type: EXPERIMENTAL): Single oral dose
- 30 mg ITI-214 (Type: EXPERIMENTAL): Single oral dose
- 75 mg - 150 mg ITI-214 (Type: EXPERIMENTAL): Single oral dose
- Placebo (Type: PLACEBO_COMPARATOR): Single oral dose

Based on this trial design, predict the completion outcome and termination type (if applicable).